Bio-Thera Reports First Patient Dosing in P-III Study for BAT2206 Proposed Biosimilar of Stelara (ustekinumab)

 Bio-Thera Reports First Patient Dosing in P-III Study for BAT2206 Proposed Biosimilar of Stelara (ustekinumab)

Bio-Thera Reports First Patient Dosing in P-III Study for BAT2206 Proposed Biosimilar of Stelara (ustekinumab)

Shots:

  • The first patient has been dosed in a P-III clinical study evaluating the efficacy and safety of BAT2206 vs reference Stelara in ~ 472 patients with moderately to severely PsO
  • BAT2206 represents the 4th biosimilar of Bio-Thera’s portfolio to enter P-III study. The advancement of BAT2206 in P-III study demonstrates company’s commitment to develop biosimilars to expand patient access at lower costs
  • Bio-Thera Solutions is developing additional proposed biosimilars, including a bevacizumab biosimilar and a tocilizumab biosimilar that have completed global P- III clinical trials. The company is also pursuing biosimilar versions of golimumab, mepolizumab, and dupilumab

Click here to­ read the full press release/ article | Ref: Businesswire | Image: Businesswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post